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THE USE OF CONTROLS IN THE 
ASSESS M ENT OF CLINICAL 
EVIDENCE 
By C. VAUGHAN RUCKLEY, M.B., CH.B. 
The prize-winning essay from the B.M.A. Essay Competition for Pro-
visionally Registered General Practitioners. 1961. The essay is abridged. 
The incorporation of standards or controls into clinical experimentation has 
become, RYer the past decade, a widely accepted practice. So much so that 
there is a danger that the medical profession in general may become uneritical 
of the practical and, more important, the ethical problems LQYROYHG The 
subject should be under constant UHYLHZ
Arc controls really necessary? How best can they be employed ? I low is 
the resulting HYLGHQFH to be assessed? Under what circumstances can the 
use of controls be justified on ethical grounds? 
THE NEED FOR CONTROLS 
Progress in medicine depends upon experiment. Formerly the physician 
based his belief in the efficacy of his simples and mixtures upon either the 
dogma of his mentors, hallowed by time and seldom criticised, or his own 
observations upon indiYidual patients. This has led to the perpetuation, eYHn 
into this supposedly enlightened age, of many remedies whose true worth 
has QHYHU been accuratclv assessed. 
Although the majorit\ of the remedies inherited from the H)th century 
and beyond KDYH been discarded with the UHYLVLRQ of the pharmacopoea in 
19 5  the need for objectiYe assessmeQt of the drugs we prescribe has QHYHU
been greater. The reasons for this DUH twofold. 
The drug houses DUH pouring out HYHU\ day a flood of new preparations. 
many of which DUH either pharmacologically identical or differ, one from the 
other, by only a small degree in action or in side effects. This is too much for 
the practitioner to sort out for himself. Even if he had the time and energy 
he might not by now have the inclination, for the extravagant claims made on 
behalf of so many products can breed a cynical i1 .uffcrencc, and a UHYHUVLRQ
to well-tried medicines. 
I le needs therefore a guide for speedy reference. Though he may uot he 
trained in statistics, if he knows that a drug has been assessed by a standardised 
scientific procedure, such as a controlled trial, his problems and his scepticism 
are much diminished. 
The second reason is an economic one. That the best W U H D W P H Q W  should 
speedily be selected from a multiple choice is very relevant to the cost of the 
l Iealth Service in this country. Not only should the best be propagated. but 
the less effective products should just as quickly be discarded. 
In diseases where no effective treatment exists, especially when they arc 
either so trival as to inconvenience the patient only a little, such as the 
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common cold, or are highly malignant, such as acute leukaemia, there m a y be 
no necessity o r indeed justification for the inclusion of a control group i n a 
trial. 
T/ lE CONCEPT OF CONTROLS 
The first clear definition of clinical controls has been attributed to Laplacc 
in 1814. "To determine the best of several treatments it is sufficient to tr\' 
each of them on the same number of patients, keeping all conditions con-
stant ... the superiority of the most beneficial treatment will manifest itself 
the more, the greater the number of cases." 
This concept has gained widespread acceptance only during the past ten 
years. It continues to have its foes. Basically it involves the application of a 
statistical method to experimentation with human subjects in a manner pre-
viously applied only to animal studies. Planning the experiment is now 
recognised to be a major undertaking, necessitating from the start having a 
clear grasp of the questions it is hoped to answer, and proceeding to detailed 
specification of the kind of subjects to he incluclcd, the treatment to be 
compared and the measurements to be t a k e n The points at which different 
types of trial arc particularly vulnerable to bias arc more widely appreciated, 
as is the value of such precautions as randomisation, " blind " comparisons 
a n d the inclusion of placebos. The nu:nbcr of successfully completed trials is 
growing and they serve as models for future work. 
ERROR 
W i t h the exceptions already mentioned, the inclusion of controls is essential 
for every kind of clinical trial. Where no control is exercised other than the 
subjective response of the patient and the clinical impression of the physician, 
the scope for error is great. 
Many investigations into observer variation have emphasised the need to 
substitute the experimental for the observational approach. 
Professor Hill has pointed out, however, that " within the framework of a 
clinical trial designed to contrast one group with another there is nothing 
whatever to inhibit the highly gifted clinical observer from observing ... " 
The observational and experimental techniques arc not mutually incompatible; 
indeed I believe one advantage of the development of controlled trials in 
Great Britain has been the need for. and the attempt to improve, observations 
of disease and disease processes. 
"The emphasis placed on objective measurements," writes Oswald Savage
" has alreadv resulted in more careful and accurate studies in these chronic 
diseases and  has already produced new observations on the natural history of 
conditions such as arthritis." 
The principle of therapeutic control is to provide for the group of patients 
who arc to undergo a new and yet untried treatment a parallel group of cases 
similar in all respects, that is as regards all possible contributing causes except 
the one factor of treatment ; or if the bchaviour of the disease in a particular 
patient is to be observed before and after treatment, to make conditions the 
same in both periods except again for the factor of treatment. 
Some sources of error may be unsuspected until the control method brings 
them to light. They represent all conditions which may be important for the 
origin as well as for the further development of the disease. Sources of error, 
or" concurrent causes," arc divided by llcrclan into 'internal' and 'external' 
causes. 
Among the internal causes arc firstly, the characteristics of the patient. 
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These include sex. age. nutrition and g e n e t i c  constiWXtion-DOl of Zhich P D \
influence profoundly his response to disease and its therapy. 
Secondl\'. thHre arH thc charactHristics of the disease itsclf .. $Wdifferent 
periods of time and in cliffercnt subjccts. particuODUly in chronic diseases. or 
in trials FRYHULQJ VHYHUDO months or years. the GLVHDVH may YDU\ in its stages, in 
its degree of VHYHULW\ D Q G in the YirulHncH of an infecting organism. Delay 
in treatment will also alloZ HYROution in the disHasH process, and ZLOO DOWHU its 
response to treatment. 
r\mong HxtHrnal causes arH firstly HQYiroQPHntal factors such as financial 
conditions, family affairs, conditions of Hmploy PHQW and Yarious physical dis-
lmbanccs which may substantially affect the SURJUHVV of thc disease. 
Causes may be introduced through the WUHDWPHQW itsclf. These include the 
effects of transition from home to hospital - the Y H U \ fact that a patient 
is PRYHG into a hospital HQYLURQPHQW can HYRNH new mental D Q G physical 
UHVSRQVHV as also F D Q the attitudes of doctors and nurses. For HxamplH, in DQ
organic cliscasc such as XOFHUDWLYH colitis where psychical factors arH known 
to play an important part, HYHQ a GXPP\ tablet. if UHFRPPHQGHG \\'ith con-
Yiction and enthusiasm by the physician, may HYRNH a perceptible clinical 
LPSURYHPHQW Thus in certain trials QHLWKHU the doctor nor the patient should 
NQRZ whether he belongs to the WULDO or the control group, nor HYHQ in the 
c a s e of the patient, that such D dichotomy exists ; hence the use of WKH
'double blind' method and dummy tablets. 
It is not correct to assume that by i n t r o d u c i n g clinical controls into a 
WULDO we automatically eliminate error. I +owerHr large a trial, and hRZeYHr 
VLPLODU control and trial groups may be. RZLQJ to the operation of concurrent 
c a u s e s it m a y lack generality. That is to say that the results, although true for 
a SDUWLFXODU time, place and trial. may not be XQLYHUVDOO\ true. 
The science of FRPSDUDWLYH therapeutics i n v o l v e s the study of just such 
larger problems. I +RZHYHU comparatiYH therapeutiFV apart, it is probably truc 
to say that the larger DQG more widespread a trial, thc more reliable DUH its 
conclusions. Examples of two such experiments DUH the M.R.C. trial of 
ACTII. cortisone and aspirin in acute rheumatic IHYHU  which in-
YROYHG the co-operation of many centres in the United Kingdom and the 
United States, and secondly the trial of the Salk polio YDccinHs which LQYROYHG
many thousands of patients. 
Tl JE CONSTRUCTION OF CO1TROLLED TRIALS 
According to the type of disease w e  are studying, so a particular type of 
trial is adopted and a particular statistical method applied to the analysis of 
the results. There are two broad categories: "within-patient" trials, where the 
patient is his own control, and " b e t w e e n  - p a t i e n t " trials, where control and 
trial are different patients. 
Tt seems agreed by most authorities that in clinical t r i a l s as in experimental 
pharmacology, when feasible, comparisons of t r e a t m e n t s  should be made 
within subjects rather than between subjects. If each subject receives all the 
treatments, variations in level of response from subject to subject cancel o u t
when treatment averages are compared. The gain in precision is often 
striking ( 5) . 
A within-subject trial is a simple example of grouping. The general principle 
is to divide the patients into groups such that differences between groups 
rcprcscnt important sources of variation that may inflate the experimental 
errors-that is, they are stratified according to known concurrent causes-
then, if the experiment can be conducted so that each treatment is represented 
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equally often in every group, differences between groups are automatically 
eliminated from the comparisons of the treatment averages. 
There are various designs by which grouping may be applied. A basic form 
is the simple cross-over pattern where the patients, and the duration of the 
trial, arc divided into two for the co:nparison of two drugs. For example. 
100 patients are included for the testing of 2 drugs over a period of 6 months. 
For the first 3 months 50 patients. who may either be randomly selected or 
subgrouped according to some common characteristic, arc given drug A and 
50patients drug B. For the second 3 months the treatments are reversed. The 
patients arc their own controls. 
The same principle can be applied in various more complex designs. An 
example of a trial may illustrate the method. The relative values of Phen-
metrazine and Dcxamphctaminc in the management of obesity have recently 
been compared (6). A 'double blind ' procedure was used. Three series of 
tablets of similar appearance were prepared :- Phenmetrazine, Dexamphet-
amine a n d a control placebo, containing principally Lactose. A crossover 
technique was employed on the latin-squarc pattern. 
1. A.B.C. 2. B.C.A. 3. C.A.B. 
The patients were allotted to a particular treatment by a random sequence 
using a table of random numbers (Bradford Hill, 1955). Thus the two treat-
ments under review were compared one with the other, and in addition, each 
patient was his own control. W i t h the use of such control grouping far more 
information can be gained than simply the quantitative success of one treat-
ment over another. 
All patients throughout the trial were on a similar low caloric diet. As is 
always the case with the initiation of a reducing diet, regardless of the drugs 
given, the weight loss in all groups was greater during the first 6 weeks, due to 
initial dehydration. Since the precise effect of a treatment dcpcudcd upon two 
things, namely the kind of tablet taken and whether it was admiuistcrcd in 
the first, second or third period, a more accurate result could be obtained if 
these two influences were disentangled. Grouping made this possible. 
Thus an important concurrent cause could be eliminated, namely the 
evolution of the disease process at a particular time in the trial-in this c a s e
the regression of weight loss-and appropriate statistical correction terms
could be applied. The conclusions drawn at the end of such a trial are 
therapeutically and statistically reliable. 
In general, it is seldom possible to apply these within-subject methods to 
acute or rapidly progressive diseases. T n fact, in clinical practice, as Doll has 
pointed out, the opportunities arc few for using the patient as his own 
control because "when one drug has been tested the patient's condition is 
likely to be so altered, whether by the drug or by nature is immaterial, that 
nothing is to be gained by repeating the treatment with another drug." (7). 
The majority of trials therefore have to be conducted by giving trial and 
control drugs to different patients. that is between-subject trials. The groups of 
patients should be similar in all respects except the treatment they rccci\'c. 
In the past, controls were often rctrospccti\'c, that is to say, attempts were 
made to compare the effects of a ne\\' drug on a group of patients o v e r a 
period of time with the effects of a previous treatment and a different group 
of patients. This, as Armitagc (8) and others have pointed out. is a practice 
which should be avoided because other factors may be operating. 
For example, patients treated with anticoagulants for coronary thrombosis 
have been compared with ' control ' groups treated prior to the introduction 
of anticoagulants in 1948. It has been sho\\'n that these two groups can not 
be fairly compared. The very fact that a specific treatment for thrombosis was
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available meant that after 1948 a larger number of coronary thromboses of only 
moderate severity were admitted to hospital than previously This alone was
sufficient significantly to improve the survival rate of cases treated in hospital. 
To avoid these and other difficulties in between-patient trials a variety of 
methods of random selection h a v e been devised. Randomisation precludes the 
possibility of conscious or unconscious bias on the part of the clinician who is 
allotting patients to the trial. 
Randomisation does not ensure that all groups a r e exactly equal; nothing 
can do this. It does ensure that t hey differ by an extent that is prcclictahlc and 
can he allowed for in the statistical analvsis. 
It may be thought preferable to take into account all the concmrent causes 
over which w e have some control by methods of sub-grouping or stratification. 
This is particularly valuable where the numbers involved a r e small and where
it is less likely that ' by chance' the two groups will be homogeneous. This 
sub-grouping can be incorporated into the system of alternates-known as 
compensating alternates-or can be combined with the random numbers 
method, especially if more than two sub-groups or strata a r e contemplated. 
Two or more groups which at the commencement of a trial appear to be 
quite comparable may show, on reassessment at the end, to differ in important 
respects. In the M.R.C. trial in 19;;, some 500 children were divided into 
three groups to compare the value of ACTH, cortisone and aspirin in the 
treatment of acute rheumatism. It was found that most of the concurrent 
causes were strictly comparable, but a marked difference happened to be
present between groups in the numbers presenting with chorea (ACTH, 5.6%: 
cortisone, 11.4% : aspirin, 1 5 . 5 % )  and with congcsti,·c heart failure (ACTI-1, 
1_4.2% : cortisone, 9%1 • aspirin, 6% ). This difference is statistically significant 
and could therefore influence results, and it illustrates the value of sub-
grouping. <9l 
Doll points out, however, that it is seldom necessary to have more than 
a few subgroups, and that if it seems necessary to have a large number 
it suggests that the tre:1tment is being tried on too heterogeneous a group of 
patients. 
A statistical method which has been increasingly used in recent years is 
Sequential Analysis. The usual practice in trials is to postpone conclusions 
until final measurements from all subjects have been gathered. In a sequential 
trial on the other hand, a continuous statistical analysis is made as the data 
from each subject comes in. The trial is stopped ·as soon as the analysis 
indicates a clear-cut verdict of statistical significance. 
This method may allow a reduction in amount of experimentation by 
10- 5 0 % as compared with a fixed-size trial of the same discriminating power.
For its suitable application there arc certain requirements:-
(i) Patients enter the trial in sequence o v e r a period of time. 
(ii) Results should be quickly available.
(iii) There should be potent reason for wishing to stop the trial as soon 
as possible. 
( iv) The primary object should be to perform a test of significance 
between new and standard treatments rather than a quantitative
asscssmcn t ( 1 o). 
The controls in sequential trials a r e the patients on the standard treatment. 
Sequential Analysis is the method used in the Stilboestrol-Oestriol trial in 
metastatic mammary carcinoma, which is currently being conducted in 
Edinburgh. It provides a good illustration of the technique. 
It is designed to show whether there is any significant difference between 
therapy with a synthetic oestrogen. stilboestrol, and a naturally occurring one. 
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oestriol. The former is the standard control. Patients are allotted to one or 
other group by a ·double blind' method. The t a b l e t s similar in appearance
arc distributed by the scaled envelope system using a table of randomised
numbers and applied by a statistician. 
In order that progress can be assessed with some accuracy the criteria of 
admission to the trial are clearly defined, principally definite skin recurrence 
and I or mctastases clearly seen on X-ray. 
Each patient is seen at monthly intervals. The nosographic criteria of pro-
gress arc based on X-ray changes, measurements of skin lesions, including 
photographic records and b i o c h e m i c a l t e s t s They arc assessed n o t by o n e b u t
by a panel of doctors. As soon as 1t 1s clear that a patient IS cletcnoratmg 
despite the hormone therapy she is withdrawn from the trial. 
THE STATISTICAL EVALUATION OF RESULTS 
The construction of therapeutic trials implies a twofold control. The two 
control concepts may be distinguished by the names of ' clinical controls ' and 
'chance controls'. 
Having arrived at the end of a trial with a quantitative difference in results 
between trial and control groups, the question then arises as to whether such 
differences can be regarded as significant. The alternative is that the differ-
ences observed arc caused bv fluctuations of the manv causes which comprise 
'chance '. 
Hence just as important as the clinical control is the control of the observed
differences, and this is affected by application of a calculated standard error or 
standard deviation. 
There arc three main types of fluctuations or variations of numerical 
quantities which obey the laws of chance:-
1. Random sampling fluctuations of numbers and of relative frequencies 
( perccn tages). 
2. Biological variations of counts and measurements. 
3· Experimental and observational errors. 
Once :1 difference has been observed between the fincliugs in the control 
group and in the tr.ial group, a statistical significance test must be applied. 
The appropriate test depends upon the particular nosographic criterion by 
which the effect of treatment is being a s s e s s e d For example, differences in 
relative frequencies or of percentages of outcome arc assessed by the standard 
error of a perccutagc and by the chi-square test, and differences ·between aver-
age duration of a disease by the standard error of the mean test. 
For most practical purposes, having established a distribution curve from 
one control group we can draw an arbitrary l ine at a distance of two standard 
deviations from the mean. If an observed value from the trial group lies out-
with this line it has a 95% chance of being statistically significant. If it lies 
beyond thrice the standard deviation it has a 99·7% likelihood of being 
significant. 
ETHICAL PROBLEMS 
The foregoing discussion has centred upon some of the problems which 
arise with the use of controls, their application and assessment. Considerations 
remain of far g r e a t e r i_mportancc. They arise in clinical experimentation 
because of our bchcf, w1th Kant, that every human being, irrespective of his 
mental or social s t a t u r e should be regarded as equally important. 
It has b e e n said t h a t many of the great men of history were great because 
they were btgots ; that 1s to say they could only see one side of a problem, their 
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own sick. In the same way. anyone. whateve r his sphere of activity, dedicated
in the pursuit of a policy or line of investigation. may become blind to points 
of view differing from his own. 
Since this may be a quite subconscious process, such a person may bitterly
resent the imputation that he is not fit to assess objectively the ethical 
implications of his own work. 
Since the use of controls has assumed an integral part of clinical experiments 
it is very relevant, in discussing their use. to consider the ethics upon which 
human experimentation as a whole is based. 
Can we justify experiments on humans at all ? I have discussed earlier some 
of the material reasons why controlled trials arc necessary in the propagation 
of new therapy. These trials cannot be confined to experimental animals. Find-
ings in other species m a y have general or specific validity for man, but the 
ultimate estabiishment of such validity must rest in each instance upon direct 
observations upon man. 
Shimkin has advanced important considerations for the justification of such 
experimentation. He points out that an unwillingness to experiment carries 
with it as much moral responsibility as active experimentation. He says, " ... 
to do nothing, or to prevent others from doing anything, is itself a type of 
experiment ... " and goes on : 
" As much knowledge and as weighty reasons arc required for one course of 
action as for the other, and it should be demonstrated that the proposed 
experiment is more dangerous or more painful than the known results of 
inaction " ( 11). 
The Nuremberg Medical Trials resulted in the formulation in 1947 of the 
oft-quoted rules which serve as a guide, though not necessarily as an infallible 
credo, for the experimenter. Shimkin has reduced these rules to two primary 
principles :-
1. "Investigators must be thoroughly trained in the scientific disciplines of 
the problem, must understand and appreciate the ethics involved, and 
must then be competent to undertake and carry out the experiment. 
2. The human experimental subjects must agree to the procedure and 
must not he selected upon any basis such as race, religion, level of educ-
ation or economic status. In other words, the investigators and their 
subjects arc human beings with entirely equal, inalienable rights that 
supersede any considerations of science or general public welfare." 
How can the use of patients as controls be reconciled with such principles ? 
Guttentag has drawn a distinction between the 'phvsician-fricnd' and the 
'physician-experimenter '. The former has a personal relationship with his 
patient, sharing his distress and wanting to assist him. "Objective experiment-
ation to confirm or disprove some doubtful or suggested biological general-
isation is foreign to this relationship. This would involve taking advantage of 
the patient's cry for help and of his insecurity" ( 12). 
'!'here is no doubt that among medical research workers in this country 
there is a tcndcncv to regard patients as experimental objects, rather than 
human beings, and since this attitude is principally to be observed in the 
teaching hospitals it may well be spreading. 
'I 'he responsibility for care of the patient, and for intensive i n v e s t i g a t i o n
or experimental procedures on that patient, should he in the same hands, not 
necessarily the hands of an individual but preferably of a group. The more 
extensive and potentially dangerous the experiment, the more widely shoulcl 
the responsibility be divided. The nature of the doctor-patient relationship is 
such that nothing ought ever to be done to the patient except to his direct· 
advantage, unless he gives his consent. As Fox has put it. "it is this consent 
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that changes his status to that of YolunWHHr, in ZKLFK he becomes the legitimate 
object of experiment." (13) 
Griener has listed the circXmstancHs under ZKLFK he considers that a com-
promise may fairly be reached. 
" J n the first place, the risk of drug toxicity must not exceed that ruQ by 
thousands of patients under FRQYHQWLRQDO treatment. In the U.S . $ this means 
drugs and doses that ha\'c already been accepted by Government agencies. 
"Secondly, each patient-participant shall have a medical condition w h i c h
in the ordinary course of events, would be treated by the test agent or another 
drug with similar action. 
"Thirdly, the experimental design shall not permit deterioration of the 
medical condition. 
"Finally, it is apparent that a number of trials would be impracticable if 
the patient understood exactly the nature of the experiment, or even that he 
were participating in an experiment at all. A U L J L G ethical ideal may be too 
restricting when facing real-life problems." As Grciner succinctly puts it, "a 
workable standard appeals to me even more than lip-service t o a remote 
principle, however perfect." ( ) 
The very fact of an experiment being necessary implies that one treatment 
is inferior to the other, and therefore that one group of patients will dcri\'c 
more benefit than the other. As long as it is only known for certain to be 
true in retrospect, then the experiment can be entirely justified on ethical 
grounds. 
W h i l e the trial group rccci\'c the new treatment the control group arc 
given the best orthodox treatment. Crofton has said that since the control 
group receives the best treatment previously available it is the safest group 
from the patient's point of view to belong to. " He may be denied the still 
improved advantage of the n e w treatment but he avoids its possible side 
effects. And, of course, the new treatment may prove to be inferior to the old." 
Finally, if we reject controlled clinical trials as ethically inadvisable, what 
arc we to propose as the alternative? Without controls, trials arc unreliable; 
without trials the distribution of drugs may be haphazard and potentially 
G D Q J H U R X V  To quote from Hill, " in many settings the carefully designed con-
trolled trial is far more ethical than the uncontrolled experimentation with 
unproven products to which patients arc frequently exposed." ( 1 ) 
It is not sufficient simply to take a passive role nor to obstrnct those who 
arc active in the development of n e w experimental methods. W e have an 
obligation not merely to reap what has been sown, but to plough-under a little 
more untillccl land for the next crop. 
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